Grifols S.A. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 8 of 8 Posts
Grifols Announces FDA Approval Of Subcutaneous Immunoglobulin Xembify
Article By: The Fly Thursday, July 4, 2019 4:25 PM EST
The company plans to launch Xembify in the United States in the last quarter of 2019 and is working with healthcare authorities to obtain approval in Canada, Europe, and other markets.
In this article: GRFS
Read
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS
Article By: ChinaBio® Today Saturday, March 9, 2019 4:13 PM EST
Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Chinese blood plasma company Shanghai RAASfor $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in Grifols Diagnostic Solutions for the RAAS stake.
In this article: CASI, BGNE, GRFS, NVO
Read
Grifols In Talks For $5B Stake In China's Shanghai RAAS Blood Products
Article By: The Fly Friday, November 23, 2018 11:30 AM EST
Grifols would invest in Shanghai RAAS by means of the contribution of its fully owned U.S. subsidiary, Grifols Diagnostic Solutions.
In this article: GRFS
Read
Grifols, S.A.: Success Is In Its Blood
Article By: Fredrik Arnold Friday, February 23, 2018 6:59 AM EST
Today I'm reviewing a biotechnology company, Grifols, S.A. Its trading ticker symbol is GRFS.
In this article: GRFS
Read
3 Biotechnology Stocks To Buy On This Biotechnology Breakout
Article By: Taki Tsaklanos Thursday, June 22, 2017 9:11 PM EST
The biotechnology stock sector is breaking out. After 20 months of consolidation “everyone” forgot about biotechnology stocks, the former leading stock market sector. As it always goes the bull breaks out once all interest is gone.
In this article: RGEN, AMGN, GRFS
Read
5 European Stocks To Buy As Trump Rally Weakens
Article By: Swarup Gupta Wednesday, March 8, 2017 3:53 AM EST
The only risk which continues to hover on the horizon for Europe’s stocks is the impact of a change in governments across key economies of the region.
In this article: GRFS, MT, RENX, TEF, HVRRY Also: DB, JPM
Read
The 2016 Small-Cap Biotech Watchlist Debuts At The Biotech Showcase
Article By: The Life Sciences Report Wednesday, January 27, 2016 6:16 PM EST
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good producing value for investors.
In this article: AZN, NVO, SGYP, SNY, CRMD, ORMP, CMXHY, SRNE, ALNY, ARRY, INCY, IRWD, PTIE, REGN, VRTX, AGEN, GALE, GRFS, PPHM, EVOK, ADMA, AKBA, VSTM, AST, RXDX, AGTC, NK, WVE, FATE, FLKS
Read
The End Of Google’s Reign Is Near
Article By: InvestorsAlley Sunday, March 15, 2015 3:23 PM EST
The end of Google’s reign as the king of search is near. Competitors are eating away market share and growth is sputtering. Trying to cherry-pick the next winner in search, however, is akin to rolling dice at a casino.
In this article: GOOG, AAPL, AOL, TWTR, FB, YNDX, BIDU, ALXN, GRFS, SPY
Read
1 to 8 of 8 Posts